Princeton Chemistry's new two-month summer program draws faculty and students from moderate to small research institutions that serve historically underrepresented groups.
Barer Institute Announces Licensing Agreement with Princeton University s Office of Technology Licensing for SHMT Inhibitor Program
News provided by
Share this article
Share this article
NEWARK, N.J., Dec. 22, 2020 /PRNewswire/ The Barer Institute, a cancer drug development initiative of Rafael Holdings, Inc., (NYSE: RFL), today announced that it has reached an agreement with Princeton University s Office of Technology Licensing for technology from the laboratory of Professor Joshua Rabinowitz, in the Department of Chemistry, Princeton University, for an exclusive worldwide license to its SHMT (serine hydroxymethyltransferase) inhibitor program and related intellectual property.
SHMT is critical source of 1–carbon units utilized in cellular nucleotide synthesis. SHMT isoforms are upregulated in numerous cancers and have been shown to be a valuable target for metabolic cancer treatment.